MRD in Relation to Transplantation and Cell Therapy

In this latest episode of ASTCT Talks, Dr. Andrés Gómez De León sits down with Dr. Aaron Logan to discuss development of current techniques for quantifying measurable residual disease (MRD) in acute lymphoblastic leukemia and MRD's relation to transplantation and cell therapy. They discuss the concept of MRD and its relevance in the treatment of leukemia as a prognostic marker and to help guide clinical decision-making, as well as the future of MRD research and more. About Dr. Andrés Gómez De León Dr. Andrés Gómez De León (@GomezDLeonMD) is an Associate Professor at Universidad Autonoma de Nuevo Leon in Monterrey Mexico and an ASTCT Content Committee member with an interest in acute leukemias and transplant and cell therapies in low and middle income countries. About Dr. Aaron Logan Dr. Aaron Logan (@hemedoc) is an Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF). His clinical practice focuses on the management of patients with acute leukemias, myelodysplastic syndrome, aplastic anemia and hemophagocytic lymphohistiocytosis. As a clinical investigator, Dr. Logan's clinical research endeavors focus on the conduct of clinical trials for therapy of acute leukemia and management of complications of allogeneic transplantation, including graft-versus-host disease. Dr. Logan also runs a research laboratory and is Director of the Hematologic Malignancies Tissue Bank at UCSF. His work focuses on the application of immunoreceptor gene profiling using next-generation sequencing and other techniques to quantify measurable residual disease in lymphoid malignancies, quantify B and T cell immune reconstitution after allogeneic hematopoietic cell transplantation, and to quantify and track malignancy-, pathogen-, and autoantigen-targeted immune responses following transplantation or immunotherapy.

There are no comments yet.

Please log in to write the first comment.